Cargando…

Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?

Hematopoietic cell transplantation (HCT) is a last treatment resort and only potentially curative treatment option for several hematological malignancies resistant to chemotherapy. The induction of profound immune regulation after allogeneic HCT is imperative to prevent graft-versus-host reactions a...

Descripción completa

Detalles Bibliográficos
Autores principales: Plantinga, Maud, de Haar, Colin, Nierkens, Stefan, Boelens, Jaap Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032952/
https://www.ncbi.nlm.nih.gov/pubmed/24904573
http://dx.doi.org/10.3389/fimmu.2014.00218
_version_ 1782317730749218816
author Plantinga, Maud
de Haar, Colin
Nierkens, Stefan
Boelens, Jaap Jan
author_facet Plantinga, Maud
de Haar, Colin
Nierkens, Stefan
Boelens, Jaap Jan
author_sort Plantinga, Maud
collection PubMed
description Hematopoietic cell transplantation (HCT) is a last treatment resort and only potentially curative treatment option for several hematological malignancies resistant to chemotherapy. The induction of profound immune regulation after allogeneic HCT is imperative to prevent graft-versus-host reactions and, at the same time, allow protective immune responses against pathogens and against tumor cells. Dendritic cells (DCs) are highly specialized antigen-presenting cells that are essential in regulating this balance and are of major interest as a tool to modulate immune responses in the complex and challenging phase of immune reconstitution early after allo-HCT. This review focuses on the use of DC vaccination to prevent cancer relapses early after allo-HCT. It describes the role of host and donor-DCs, various vaccination strategies, different DC subsets, antigen loading, DC maturation/activation, and injection sites and dose. At last, clinical trials using DC vaccination post-allo-HCT and the future perspectives of DC vaccination in combination with other cancer immunotherapies are discussed.
format Online
Article
Text
id pubmed-4032952
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40329522014-06-05 Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control? Plantinga, Maud de Haar, Colin Nierkens, Stefan Boelens, Jaap Jan Front Immunol Immunology Hematopoietic cell transplantation (HCT) is a last treatment resort and only potentially curative treatment option for several hematological malignancies resistant to chemotherapy. The induction of profound immune regulation after allogeneic HCT is imperative to prevent graft-versus-host reactions and, at the same time, allow protective immune responses against pathogens and against tumor cells. Dendritic cells (DCs) are highly specialized antigen-presenting cells that are essential in regulating this balance and are of major interest as a tool to modulate immune responses in the complex and challenging phase of immune reconstitution early after allo-HCT. This review focuses on the use of DC vaccination to prevent cancer relapses early after allo-HCT. It describes the role of host and donor-DCs, various vaccination strategies, different DC subsets, antigen loading, DC maturation/activation, and injection sites and dose. At last, clinical trials using DC vaccination post-allo-HCT and the future perspectives of DC vaccination in combination with other cancer immunotherapies are discussed. Frontiers Media S.A. 2014-05-19 /pmc/articles/PMC4032952/ /pubmed/24904573 http://dx.doi.org/10.3389/fimmu.2014.00218 Text en Copyright © 2014 Plantinga, de Haar, Nierkens and Boelens. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Plantinga, Maud
de Haar, Colin
Nierkens, Stefan
Boelens, Jaap Jan
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title_full Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title_fullStr Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title_full_unstemmed Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title_short Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
title_sort dendritic cell therapy in an allogeneic-hematopoietic cell transplantation setting: an effective strategy toward better disease control?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032952/
https://www.ncbi.nlm.nih.gov/pubmed/24904573
http://dx.doi.org/10.3389/fimmu.2014.00218
work_keys_str_mv AT plantingamaud dendriticcelltherapyinanallogeneichematopoieticcelltransplantationsettinganeffectivestrategytowardbetterdiseasecontrol
AT dehaarcolin dendriticcelltherapyinanallogeneichematopoieticcelltransplantationsettinganeffectivestrategytowardbetterdiseasecontrol
AT nierkensstefan dendriticcelltherapyinanallogeneichematopoieticcelltransplantationsettinganeffectivestrategytowardbetterdiseasecontrol
AT boelensjaapjan dendriticcelltherapyinanallogeneichematopoieticcelltransplantationsettinganeffectivestrategytowardbetterdiseasecontrol